COVID-19 vaccine candidate is 96.4 percent effective in mice, study shows
Administering two doses of a COVID-19 vaccine called BVX-0320 is effective in mouse models, a pre-clinical study has shown.
List view / Grid view
Administering two doses of a COVID-19 vaccine called BVX-0320 is effective in mouse models, a pre-clinical study has shown.
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
This article summarises the development and testing of a novel vaccine that could be personalised for the treatment of immunotherapy-resistant cancers, such as triple-negative breast cancer (TNBC).
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
By targeting the mutated KRAS gene, researchers have developed an experimental vaccine that protected mice against a range of cancers.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
Researchers have screened small molecule libraries and then applied hit-to-lead approaches to discover effective vaccine adjuvants.
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
Researchers used CRISPR gene-editing to develop a vaccine able to protect against the spread of the Leishmania major parasite which causes cutaneous leishmaniasis.
The World Health Organization (WHO) identifies leishmaniasis as a neglected tropical disease for which new treatments are vitally needed. Leishmaniasis primarily affects people in South America, East Africa and Asia, especially those weakened by malnutrition and poverty. To help those with this disfiguring and potentially life-threatening parasitic disease, the European…